Genomma Lab Internacional SAB de CV (FRA:GEKA)
€ 1.22 0.01 (0.83%) Market Cap: 1.20 Bil Enterprise Value: 1.42 Bil PE Ratio: 16.59 PB Ratio: 2.41 GF Score: 70/100

Q3 2024 Genomma Lab Internacional SAB de CV Earnings Call Transcript

Oct 24, 2024 / 05:00PM GMT
Release Date Price: €1.17 (+6.36%)

Key Points

Positve
  • Sales increased by 15.9%, driven by strong performance in major markets such as Mexico, Brazil, Argentina, and the US.
  • Gross margin improved by 184 basis points, reaching 64.3%, indicating successful productivity initiatives and manufacturing efficiencies.
  • EBITDA expanded by 245 basis points to 23.7%, reflecting effective cost management and operational improvements.
  • Net income surged by 78.1%, with earnings per share growing by 81.6%, showcasing strong financial performance.
  • Cash flow generation reached a record high of MXN2,404 million, representing a 68.1% increase, highlighting robust cash management.
Negative
  • Challenges persist in the skincare category, with expectations to resolve issues by Q2 2025.
  • Blades and razors face issues related to Celine, although sellout remains healthy in Mexico.
  • Headwinds were encountered in Peru and Chile, impacting overall regional performance.
  • Receivables increased by seven days year over year, and days payable outstanding decreased by seven days, indicating potential cash flow management challenges.
  • Forex was a headwind in Argentina and Brazil, affecting financial results in these regions.
Christianne Ibanez
Genomma Lab Internacional SAB de CV - Head of Investor Relations

Are subject to risks and uncertainties that could cause actual results to differ materially. They are also based on assumptions as of today and the company undertakes no obligation to update them as a result of new information or future events. Let me now turn the call over to Marco.

Juan Marco Sparvieri
Genomma Lab Internacional SAB de CV - Chief Executive Officer

Good morning, everyone, and thank you, Chris. I am thrilled to share our strong Q 3 2024 results.

This quarter, we have seen substantial progress across all key metrics surpassing last year's results. Previous periods and our internal targets sales increased by 15.9% driven by excellent performance in major markets such as Mexico, Brazil, Argentina and the US gross margin improved by 184 basis points reaching 64.3%.

EBITDA expanded by 245 basis points reaching [23.7%] fueled by our productivity initiatives and manufacturing efficiencies.

Net income surged by 78.1% and earnings per share

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot